Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

The Danish pharma giant finds itself under scrutiny once again- this time, from European regulators.

EU Investigates Ozempic Maker After Reports Of Suicidal Thoughts

Ozempic is under review by European drug-safety regulators after they received reports of suicidal thoughts linked to the popular weight-loss drug and another medicine in the class.

Europe Is Probing Whether Ozempic Use Raises Risk of Suicidal Thoughts

Danish firm Novo Nordisk says "patient safety is a top priority" following reports.

European regulator to review weight-loss drugs following reports of suicidal thoughts

Novo Nordisk on Thursday accused three Florida pharmacies of illegally selling products claiming to contain semaglutide, the active ingredient in the Danish drugmaker's weight loss and diabetes drugs Wegovy, Ozempic and Rybelsus.

Wegovy maker Novo Nordisk sues Florida pharmacies over copycat drugs

It has been hugely popular for weight loss even though it's not approved for that use. The drug's potential could go far beyond just weight loss and diabetes, however.

Ozempic Sales Are Soaring -- Here's Why They Could Go Even Higher

Patients taking diabetes and weight loss drugs during anesthesia may be at increased risk of serious complications like nausea and vomiting, the ASA said.

People should stop taking Ozempic, Wegovy obesity drugs before surgery, doctors group says

Eli Lilly

Investors should not bank on Medicare covering the powerful new weight-loss drugs from Eli Lilly & Co. LLY, -1.25%, Novo Nordisk NVO, +0.52% and other drugmakers any time soon, Beacon Policy Advisors said in a report Thursday. A decades-old law generally prohibits Medicare from covering prescription drugs for weight loss.

Medicare coverage of weight-loss drugs? Don't count on it, analysts say.

Altimmune

Amgen

Pfizer

Viking Therapeutics

Drug developers are chasing an obesity drug gold rush that may be worth up to $100 billion by rolling out treatments that can help lose as much as 24% of weight in less than a year.

Factbox: Weight-loss drugs: the next gold rush

Eli Lilly stock surged closer to a record high Tuesday after the company set a new bar in the industry for weight-loss medications.

Eli Lilly Sets New Bar In Weight Loss And Nears Record High; Novo Nordisk Slips

Akero Therapeutics Inc

89bio Inc

Madrigal Pharmaceuticals

Vertex Pharmaceuticals

Wall Street's obsession with next-generation obesity and diabetes treatments intensified over the weekend as drugmakers presented new clinical-trial data on the drugs — including weight-loss pills in development that could become alternatives to popular injectables like Wegovy and Ozempic.

Weight-loss drugs in development aim to replace injections with pills

Novo Nordisk (NVO) announces encouraging new data from its late-stage ONWARDS 1 and 3 studies on once-weekly basal insulin icodec against once-daily comparators at 52 and 26 weeks, respectively.

Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data

Novo Nordisk's pill is an oral version of semaglutide, the active ingredient in the Danish company's blockbuster weight loss injections Ozempic and Wegovy.

Novo Nordisk says high-dose experimental obesity pill leads to 15% weight loss

Novo Nordisk (NYSE:NVO) said on Sunday that it plans to seek US and European regulatory approval of a high-dose oral version of its wight loss drug, semaglutide. Known as Wegovy and Ozempic, the new formulation was shown to be effective in a late-stage trial.

Novo Nordisk to seek approval for oral version of top-selling weight loss treatment

Drugmaker Novo Nordisk on Sunday said a late-stage trial found that a high-dose oral version of its drug semaglutide helped overweight or obese adults lose 15% of their body weight, which is in line with recent results for other experimental obesity pills.

Novo Nordisk says obesity pill leads to 15% weight loss; availability "to be determined"

Bagsværd, Denmark, Sunday 25 June 2023 – Novo Nordisk today announced data from the phase 3a ONWARDS 1 and 3 trials evaluating investigative once-weekly basal insulin icodec, which were presented at the 83rd Annual Scientific Sessions of the American Diabetes Association (ADA). The data showed the studies met their primary endpoints, while reducing injections from seven to one per week, compared with once-daily basal insulin1,2. Additionally, data from the ONWARDS 1 and 3 studies demonstrated that more insulin-naïve adults with type 2 diabetes treated with once-weekly basal insulin icodec achieved an HbA1c target of

Novo Nordisk A/S: New data show once-weekly insulin icodec met additional endpoints in adults with type 2 diabetes in phase 3a trials

ASML Hld

BASF SE

LVMH Moet Hennessy Louis Vuitton

Nestle SA

Roche Holding AG

Europe is a relevant place for investment due to its role as one of the world's leading economic areas. Europe is home to many well-established multinational companies. Major European stock indices have a lower average valuation and a higher dividend yield than the S&P 500. However, the S&P 500 has significantly outperformed these indices in recent years. Some individual European stocks have provided a great total return over the past years. However, there are significant practical challenges linked to diverging currencies, regulations and other factors.

Investing In European Dividend Stocks - Worth The Hassle?

Novo Nordisk said on Thursday the European Union's drug watchdog had last month raised a thyroid cancer safety signal for several of its drugs including semaglutide, the active ingredient in its popular diabetes and obesity drugs, Ozempic and Wegovy.

Novo Nordisk shares slip on EMA drug safety signal

At a conference beginning Friday, Eli Lilly and Novo Nordisk will show off next-generation weight-loss drugs. Wall Street—and Hollywood—are already mad for their existing weight-loss products.

More News Is Coming on Lilly, Novo Nordisk's New Weight-Loss Drugs

Danish drugmaker Novo Nordisk initiated federal court lawsuits against medical spas and wellness clinics in New York, Texas, Florida and Tennessee.

Novo Nordisk sues clinics allegedly selling knockoff versions of Ozempic and Wegovy

Drug maker Novo Nordisk NVO, +0.28% on Tuesday sued five wellness spas and clinics in federal court, accusing them of unlawfully peddling what they said were modified copies of the popular drug Ozempic and other medications being used for weight loss, according to the Wall Street Journal. The drug maker accused those businesses of “false advertising, trademark infringement and unfair competition,” according to the Journal.

Novo Nordisk cracks down on alleged Ozempic imitations

Novo Nordisk (NYSE:NVO) executives announced on Tuesday that the launch of its obesity drug Wegovy in most of Europe will be slower than planned and the medication will likely not be sold in developing nations for a “very long time,” due to surging demand in the US following its launch there in mid-2021. Wegovy has lifted Novo Nordisk to record sales as well as its current position as the third largest pharma company globally by market capitalization, according to Refinitiv data.

Novo Nordisk says launch of weight loss drug Wegovy in new markets delayed due to US demand

Drug maker Novo Nordisk on Tuesday said it had sued medical spas and wellness clinics in the United States for selling products claiming to contain semaglutide, the key ingredient in its popular weight loss and diabetes drugs.

Novo Nordisk sues spas, wellness clinics for selling counterfeit weight-loss drugs

Initiating legal proceedings against medical spas, weight loss or wellness clinics, and compounding pharmacies to cease and desist from false advertising, trademark infringement and unlawful sales Informing the public on how to identify Novo Nordisk's authentic semaglutide injectable products in the US Providing semaglutide.com as resource hub and credible source of information in line with Company's commitment to responsible use of our medicines and patient safety PLAINSBORO, N.J. , June 20, 2023 /PRNewswire/ -- Novo Nordisk announced today that it is taking multiple actions to protect US patients from the unlawful marketing and sales of non-FDA approved counterfeit and compounded semaglutide products claiming to contain semaglutide, while reinforcing the responsible use of Novo Nordisk's FDA-approved medicines.

Novo Nordisk takes actions to help protect US patients from unlawful sales of non-FDA approved medicines claiming to contain semaglutide

Novo Nordisk's launch of obesity drug Wegovy in most of Europe will be slower than planned and the drug will likely not be sold in developing nations for a very long time, executives said on Tuesday, as demand booms in the United States.

Novo Nordisk's Wegovy launch in new markets will be slower due to high demand

Novo Nordisk is taking the launch of its obesity drug Wegovy "a little slower than planned" in new markets due to higher than expected demand in the three countries where it is currently sold, an executive said on Tuesday.

News for Novo Nordisk Stock (NVO)